Nothing Special   »   [go: up one dir, main page]

WO2018102233A1 - Therapeutical methods, formulations and nutraceutical formulations - Google Patents

Therapeutical methods, formulations and nutraceutical formulations Download PDF

Info

Publication number
WO2018102233A1
WO2018102233A1 PCT/US2017/063208 US2017063208W WO2018102233A1 WO 2018102233 A1 WO2018102233 A1 WO 2018102233A1 US 2017063208 W US2017063208 W US 2017063208W WO 2018102233 A1 WO2018102233 A1 WO 2018102233A1
Authority
WO
WIPO (PCT)
Prior art keywords
curcumin
extract
ejaculation
formulation
minutes
Prior art date
Application number
PCT/US2017/063208
Other languages
French (fr)
Inventor
Tian Xin WANG
Original Assignee
Wang tian xin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wang tian xin filed Critical Wang tian xin
Publication of WO2018102233A1 publication Critical patent/WO2018102233A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Definitions

  • the invention relates to methods and compositions of delaying ejaculation.
  • the invention relates to a method of delaying ejaculation by the administration of a tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition.
  • the compositions can also be used to treat depression.
  • Premature ejaculation is a debilitating sexual dysfunction. This dysfunction can lead to an inability to enter into, or sustain, relationships and can cause psychological damage to sufferers. Premature ejaculation can also impair reproductive success.
  • Treatments for premature ejaculation include psychological therapies, topical anesthetics, and the use of devices. All of these treatments have significant drawbacks.
  • Psychological therapies benefit only a subset of patients and require specialized therapists who may not be available to all patients.
  • psychological therapies cannot alleviate premature ejaculation resulting from non-psychological causes. Anesthetic agents decrease sensitivity of tissues, thereby diminishing sexual pleasure.
  • topical anesthetics can be transferred to sexual partners and thereby decrease their sensitivity and pleasure as well.
  • devices With regard to devices, these can be awkward, inconvenient and embarrassing to use. Devices are highly conspicuous and reveal the very condition which the suffering partner may prefer to conceal. Additionally, devices can cause irritation to one or both partners. Methods for treating premature ejaculation by systemic administration of fluoxetine, sertraline, Paroxetine, Dapoxetine and tramadol have been described. However, these drugs may not be effective for all patients, and their side effects can halt treatment or impair patient compliance. Disease states or adverse interactions with other drugs may contraindicate the use of these compounds or require lower dosages that may not be effective to delay the onset of ejaculation.
  • the current invention discloses methods, reagents and pharmaceutical formulations to treat PE (premature ejaculation) or increase the pre-ejaculation time during sexual activity. It also discloses methods, reagents and pharmaceutical formulations to treat erectile dysfunction, cancer, and depression.
  • One aspect of the current invention provides a low side effect, rapid onset composition to treat premature ejaculation or increase the pre-ejaculation time during sexual activity. It also provide a method to treat premature ejaculation or increase the pre ejaculation time during sexual activity by taking the said formulation orally within 10 hours before intercourse.
  • a preferred composition contains l ⁇ 20mg of escitalopram or 20-100mg hyperforin, and/or 100- lOOOmg Rhizoma Corydalis extract and 50- 2000mg of curcumin or curcumin salt (e.g.
  • curcumin sodium salt or curcumin derivative.
  • it can further contains 1-20 mg of piperine or turmeric oil.
  • Suitable dosage forms include capsule, liquid capsule, tablet, lozenge, liquid gel, solution (e.g. in 50% ethanol solution) and etc.
  • the formulation contains one or more antidepressant selected form natural or synthetic SNRI or SSRIs or agomelatine (Valdoxan).
  • the suitable amount of drug used in the formulation is 5% -100% dosage amount of the amount used as antidepressants.
  • Synthetic SNRI is serotonin and norepinephrine reuptake inhibitor, such as venlafaxine, duloxetine.
  • SSRIs are selective serotonin reuptake inhibitors that are generally used antidepressants. Examples of synthetic SSRIs include fluoxetine (Prozac), paroxetine (Paxil), and sertraline (Zoloft), dapoxetine, escitalopram and citalopram.
  • the formulation also contains curcuminoid polyphenol (curcumin type compound). The suitable amount of curcuminoid used in the formulation is between 20mg-2000mg.
  • Suitable curcumin type compound can be either pure curcumin (diferuloylmethane) or curcuminoid mixture (e.g. that extracted from turmeric, contains approximately 70-80% diferuloylmethane, 10-20% demethoxy cur cumin, and 5-10% bisdemethoxy cur cumin) or curcumin derivatives.
  • the pure curcumin (diferuloylmethane) performs similar as curcuminoid extracted from turmeric.
  • curcumin, turmeric extract and curcuminoid are used interchangeable in the current invention.
  • composition can further contain 1-20 mg of piperine or chavicine.
  • Piperine along with its isomer chavicine, is the alkaloid responsible for the pungency of black pepper and long pepper.
  • turmeric oil turmerne
  • turmerne can also be added to improve bioavailability of curcumin.
  • Biocurcumax curcumin mixed with turmeric oil.
  • it can further contain caffeine 20 ⁇ 200mg.
  • it can further contain cGMP-specific
  • PDE5 inhibitor phosphodiesterase (PDE5) inhibitor.
  • the suitable dose of PDE5 inhibitor is 20% -150% dosage amount of the amount used in treating erectile dysfunction.
  • Bile acid, chitin or none ionic surfactant such as Poloxamer or Tween (e.g. tween-80) can be added to the formulation to improve the absorption of the drug.
  • Example of suitable PDE5 inhibitor can be selected from avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, zaprinast and icariin.
  • Sildenafil can be added to the formulation at the amount between 10- 1 OOmg.
  • Tadalafil can be added to the formulation at the amount between lmg- 20 mg.
  • Vardenafil can be added to the formulation at the amount between 1 mg- 20 mg.
  • Suitable amount of antidepressant used in the formulation is Paroxetine 2.5-30 mg, Sertraline 5- 100 mg, escitalopram l-20mg, citalopram 2- 40 mg, dapoxetine 5-60mg, fluoxetine 5-80mg , Venlafaxine 5-30mg, duloxetine 5-60mg.
  • a volunteer took a capsule containing 10 mg of escitalopram, 500 mg of curcuminoid. After 3 hours, the pre ejaculation time was 30 minutes compared with 10 minutes previously without the drug. After 20 hours, the pre ejaculation time was 20 minutes compared with 10 minutes previously without the drug.
  • a volunteer took 10ml 50% ethanol aqueous solution containing 10 mg 85 Escitalopram and 500 mg of curcumin in the form of curcuminoid extract from turmeric. After 1.5 hours, the pre ejaculation time was 30 minutes compared with 10 minutes previously without the drug. After 20 hours, the pre ejaculation time was 20 minutes compared with 10 minutes previously without the drug.
  • a volunteer took a capsule containing 5 mg of escitalopram, 300 mg of curcuminoid extract from turmeric and 2 mg of piperine. After 3 90 hours, the pre-ejaculation time was 20 minutes compared with 5 minutes without the drug
  • the pre- ejaculation time was 20 minutes compared with 5 minutes previously without the drug.
  • a volunteer took 5ml 50% ethanol aqueous solution containing 5 mg of escitalopram, 300 mg of curcumin and 2 mg of piperine. After 1.5 hours, the pre ejaculation time 95 was 20 minutes compared with 5 minutes without the drug previously. After 20 hours, the pre ejaculation time was 20 minutes compared with 5 minutes previously without the drug.
  • a volunteer took a capsule containing 10 mg of citalopram, 500 mg of curcumin and 2 mg of piperine. After 3 hours, the pre ejaculation time was 20 minutes compared with 5 minutes without the drug previously. In another embodiment, a volunteer took a capsule 100 containing 1 mg of citalopram, 500 mg of curcumin and 2 mg of piperine. After 3 hours, the pre ejaculation time was 15 minutes compared with 5 minutes without the drug previously. The volunteer also reported improved erection.
  • curcuminoid can reduce these side effects and further improve 105 erection.
  • a volunteer took a capsule containing 3 mg of escitalopram, 200 mg of curcumin and 30 mg of sildenafil. After 2 hours, the pre ejaculation time was 20 minutes compared with 5 minutes without the drug previously. The volunteer also reported improved erection.
  • the formulation is a liquid form contains 5ml 50% ethanol, 5 mg of escitalopram, 20mg caffeine, 250 mg of curcumin and 5mg of vardenafil. The liquid can be taken by the person in need before sexual activity.
  • the formulation is a liquid capsule contains 5 mg of escitalopram, 200 mg of curcumin and 30 mg of sildenafil in 50% glycerol, 20% ethanol solution.
  • the capsule can 115 be taken by the person in need 3 hours before the sexual activity.
  • a volunteer took a capsule containing 10 mg of paroxetine, 500 mg of curcumin. After 3 hours, the average pre ejaculation time was 25 minutes compared with 10 minutes previously without the drug. The volunteer reported slight side effects (mild nausea).
  • paroxetine 500 mg of curcumin. After 3 hours, the average pre ejaculation time was 15 minutes compared with 10 minutes previously without the drug. The volunteer reported very slight side effects (very mild nausea).
  • a volunteer took a capsule containing 5 mg of 135 paroxetine, 300 mg of curcumin and 2 mg of piperine. After 3 hours, the average pre ejaculation time was 15 minutes compared with 5 minutes without the drug previously. The volunteer reported no significant side effects. In repeated experiments the same volunteer took a capsule containing 30 mg of paroxetine only and the average pre ejaculation time was 8 minutes after 3 hours compared with 5 minutes without the drug previously. However the volunteer reported 140 significant side effects (stomach irritation, nausea and headache).
  • a volunteer took a capsule containing 20 mg of dapoxetine, 500 mg of curcumin. After 3 hours, the average pre ejaculation time was 20 minutes compared with 10 minutes previously without the drug. The volunteer reported slight side effects (mild nausea).
  • a volunteer took a capsule containing 15 mg of dapoxetine, 300 mg of curcumin and 2 mg of piperine. After 3 hours, the average pre ejaculation time was 20 minutes compared with 5 minutes without the drug previously. The volunteer reported no significant side effects. In repeated experiments the same volunteer took a capsule containing 60 mg of dapoxetine only and the average pre ejaculation time was 20 minutes after 3
  • a volunteer took a capsule containing 30 mg of sertraline, 500 mg of curcumin. After 3 hours, the average pre ejaculation time was 15 minutes compared with 5 minutes previously without the drug. The volunteer reported slight side effects 155 (mild nausea). In repeated experiments the same volunteer took a capsule containing 60 mg of sertraline only and no significant increase in pre-ejaculation time was observed after 3 hours; and the volunteer reported significant side effects (stomach irritation, nausea and headache). Only after taking the 60 mg of sertraline once daily for 10 days continuously, the average pre ejaculation time was 10 minutes compared with 5 minutes previously without the drug.
  • a volunteer took a capsule containing 30 mg of duloxetine, 500 mg of curcumin. After 3 hours, the average pre ejaculation time was 10 minutes compared with 5 minutes previously without the drug. The volunteer reported slight side effects (mild nausea). In repeated experiments the same volunteer took a capsule containing 60 mg of duloxetine only and no significant increase in pre-ejaculation time was observed after 3 hours;
  • the antidepressant in the above embodiments used can be natural product or natural product extract instead of synthetic SSRI.
  • the natural antidepressant is St. John's wort extract such as those commercially available as nutraceuticals and medicines used for mood improvement.
  • the preferred dosage of St. John's wort extract used is between
  • the St. John's wort extract contains at least 3% hypericin
  • adhyperforin, pseudohypericin, and hyperforin combined weight In one embodiment, in repeated experiments a volunteer took 1 capsule containing 1000 mg of St. John's wort extract and one capsule containing 1000 mg of curcumin and 5mg of piperine. After 2 hours, the average pre ejaculation time was 15 minutes compared with 5 minutes previously without the drug.
  • St. John's wort extract contains low amount of hypericin, pseudohypericin, and hyperforin, it can be further concentrated to contain higher amount of hypericin, pseudohypericin, and hyperforin to reduce the amount of drug used
  • the main active agents in St. John's wort extract are hypericin, adhyperforin, pseudohypericin and hyperforin which can be oxidized readily therefore show reduced potency.
  • Curcuminoid is potent antioxidant which protect the active agents in St. John's wort extract from being oxidized 190 therefore improve their potency when being co-formulated and taken together. This is one of the mechanisms that curcuminoid plus St. John's wort extract shows better therapeutical efficacy than using St. John's wort extract alone.
  • Curcuminoid has low bioavailability and most of them keep intact in gastrointestinal (GI) tract, therefore can protect the drug from being oxidized for a longer time in GI tract than other antioxidant that can be absorbed in GI tract readily.
  • Curcuminoid can also be added to the formulation for other drugs to protect them from being oxidized and increase their potency.
  • composition in the current invention contains 5-100 mg hyperforin or adhyperforin or their combination. Most preferably the
  • composition in the current invention contains 10-50 mg hyperforin or adhyperforin or their
  • a volunteer took 1 capsule containing 10 mg of hyperforin from concentrated St. John's wort extract, 500 mg of cur cumin and 5mg of piperine. After 2 hours, the average pre ejaculation time was 10 minutes compared with 5 minutes previously without the drug. The volunteer reported no side effects and reported better
  • a volunteer took 1 capsule containing 10 mg of hyperforin only and after 2 hours the average pre ejaculation time was not changed compared to the time previously without the drug.
  • a volunteer took 1 capsule containing 20 mg of mixture of hyperforin and adhyperforin, and 500 mg of curcumin. After 2 hours, the average pre ejaculation time was 15 minutes compared with 5 minutes
  • hyperforin in the above embodiments can be replaced with hyperforin
  • Hyperforin derivatives/analogues can also increase the pre ejaculation time either used alone or in combination with curcumin.
  • the formulation containing both curcumin and hyperforin derivatives/analogues has better efficacy than using hyperforin derivatives/analogues alone.
  • Centella asiatica extract can be used alone or added to other embodiments in the current invention to increase the pre ejaculation time and treat depression.
  • Centella asiatica extract's active component contains Centella triterpenic genine, Asiaticoside, Madecassoside, Asiatic & Madecassic acid.
  • the composition in the current invention as oral
  • 225 formulation contains 100-5000 mg Centella triterpenic genine or Asiaticoside or Madecassoside or Asiatic or Madecassic acid or their combination.
  • a volunteer took 1 capsule containing 2000 mg of Centella triterpenic genine and after 2 hours the average pre ejaculation time was 10 minutes compared with 5 minutes previously without the drug.
  • a volunteer took 2000 mg of Centella triterpenic genine, 30mg hyperforin
  • Tramadol can be used in all the above embodiments.
  • antidepressant e.g. synthetic SSRI or St. John's wort extract
  • curcumin can be omitted from the formulation although the combination of all three is also effective.
  • tramadol is used herein to refer to 2-[(dimethylamino)methyl]-l-(3-methoxyphenyl)- cyclohexanol ("tramadol") and all pharmaceutically-acceptable forms and derivatives of tramadol.
  • the term includes the N-oxide derivative ("tramadol N-oxide") and the O- desmethyl derivative ("O-desmethyl tramadol”).
  • the term also includes the solvates, polymorphs, and pharmaceutically-acceptable acid addition salts of tramadol and its derivatives.
  • stereoisomers including individual enantiomers
  • mixtures of stereoisomers including the racemates.
  • Preferred dosage is between 5mg ⁇ 50mg.
  • a volunteer took a capsule containing 10 mg of paroxetine, 20 mg of Tramadol. After 3 hours, the average pre ejaculation time was 25 minutes 245 compared with 5 minutes previously without the drug. The volunteer reported slight side effects (mild nausea).
  • a volunteer took a capsule containing 3 mg of escitalopram, 20 mg of Tramadol. After 3 hours, the average pre ejaculation time was 25 minutes compared with 5 minutes previously without the drug. The volunteer reported no side effects. 250 While 20 mg of Tramadol only increase the average pre ejaculation time to lOmin.
  • a volunteer took a capsule containing 500 mg of curcumin, 2mg of piperine, 20 mg of Tramadol. After 3 hours, the average pre ejaculation time was 25 minutes compared with 5 minutes previously without the drug. The volunteer reported no side effects.
  • a volunteer took a capsule containing 500 mg of curcumin, 2mg of escitalopram, 10 mg of Tramadol. After 3 hours, the average pre ejaculation time was 25 minutes compared with 5 minutes previously without the drug. The volunteer reported no side effects.
  • curcuminoid can be co-formulated together or be
  • drugs having ejaculation delaying effect can also be used in combination with curcuminoid to boost their efficacy and reduce their side effect and dose.
  • these agents include but are not limited to morphine and morphine derivatives (e.g. those disclosed in 265 US patent 8,158,764), Delta opioid receptor agonist (e.g. those disclosed in US patent application 11/696,806) and certain serotonin agonists and antagonists (e.g. those disclosed in U.S. Patent 6,037,360).
  • the current invention also provides method and formulations containing curcumin and St. John's wort extract to treat depression.
  • the preferred dosage of St. John's wort extract used is between
  • curcumin extract used is between 300mg ⁇ 3000mg.
  • a patient suffering depression took one capsule three times daily and each capsule contains St. John's wort extract 300mg and curcumin 500mg. After two weeks, the patient report much improved mood and no side effects were observed.
  • Piperine 2-20mg can also be added to the formulation.
  • Morinda officinalis (Medicinal Indianmulberry Root) extract (100mg ⁇ 1000mg) can be added to the formulation.
  • the current invention also provides method and formulations containing curcumin and escitalopram to treat depression.
  • the preferred dosage of curcumin used is between
  • escitalopram used is between 5mg ⁇ 10mg.
  • a patient suffering depression took one capsule daily and each capsule contains escitalopram 5mg and 280 curcumin 500mg. After two weeks, the patient report much improved mood comparable to
  • Piperine 2-20mg can also be added to the formulation.
  • the current invention also provides method and formulations containing escitalopram and St. John's wort extract to treat depression.
  • the preferred dosage of St. John's wort extract used is
  • escitalopram 285 between 300mg ⁇ 3000mg.
  • the preferred dosage of escitalopram used is between 5mg ⁇ 10mg.
  • a patient suffering depression two capsules daily and each capsule contains St. John's wort extract 300mg and escitalopram 5mg. After one weeks, the patient report much improved mood comparable to taking escitalopram 20mg daily.
  • Curcumin 200-500mg and Piperine 2-20mg can also be added to each capsule.
  • Morinda officinalis Medicinal Indianmulberry
  • the SSRI can be replaced with one synthetic SNRI such as venlafaxine and duloxetine or Valdoxan.
  • the amount of SNRI or Valdoxan used in the formulation can be lower than they being used alone. Normally half daily dose is enough to reach the desired effect.
  • the current invention also provides formulations containing curcumin as injection dosage to treat diseases such as cancer or Alzheimer.
  • curcumin solid lipid nanoparticles which can be made by a microemulsion technique such as using microfluidizer at suitable temperature (e.g. at 25-75 degrees C).
  • the mixture can be further lyophilized to improve long term storage stability. When injected to the patient, it provides better bioavailability and better therapeutical effects.
  • composition containing both curcumin and St. John's wort extract or composition containing both curcumin and hyperforin can be used for Alzheimer treatment.
  • a capsule 305 containing 500mg curcumin, Piperine 2 mg and 500 mg St. John's wort extract can be taken
  • a capsule containing 500mg curcumin and 30 mg tetrahydrohyperforin can be taken orally 2 times a day to treat Alzheimer.
  • a capsule containing 500mg curcumin and 30 mg hyperforin can be taken orally 2 times a day to treat Alzheimer. They can be also be made in injection form to treat
  • the current invention also provides a formulation containing curcumin and cordycepin to treat cancer or reduce the side effect of radio/chemotherapy.
  • Preferred curcumin amount is between 300mg-3g, and the preferred amount of cordycepin is between 5-100 mg.
  • the cordycepin can be in the form of Cordyceps sinensis extract, Cordyceps militaris extract or those from fermentation 315 as well as synthetic cordycepin.
  • the formulation is a capsule or tablet
  • the current invention also provides a formulation containing curcumin and epimedium
  • the formulation is a capsule or tablet contains 500mg of curcumin, 500mg of Epimedium brevicornu exatrct standardized to contain 10% icariin.
  • Maca Extract 75 mg -300mg can also 325 be incorporated to the formulation. A volunteer took one capsule 3 hours before intercourse showed improved erection and slightly increased ejaculation latency. St. John's wort extract 300mg ⁇ 1000 mg can also be added to the capsule/tablet to further increase the ejaculation latency time.
  • suitable curcumin type compound can be either turmeric extract, 330 curcumin (diferuloylmethane) or curcuminoid (e.g. that extracted from turmeric, contains
  • curcumin bisdemethoxy curcumin or one or more selected from natural curcumin derivatives including curcumin metabolites including tetrahydrocurcuminoids (e.g. curcumin glucuronide, curcumin sulfate, tetrahydrocurcumin, and hexahydrocurcumin) or synthetic curcumin derivatives such as 335 curcumin mono or di glycoside, curcumin mono or di carboxylic acid ester, curcumin mono or di phosphate.
  • the curcumin (diferuloylmethane) and tetrahydrocurcumin performs similar as curcuminoid extracted from turmeric.
  • Curcumin can be in the form of one or more
  • curcuminoid/curcumin derivatives in complex with micelles, emulsion, nanoparticles, liposome and cyclodextrin such as alpha or beta-cyclodextrin or hydroxypropyl-y-cyclodextrin and
  • hydroxypropyl-beta-cyclodextrin optionally it can further contains 1-20 mg of piperine or lmg- 200mg turmeric oil.
  • the above natural products based formulations can be used as nutraceuticals without being approved as drugs.
  • Rotundine is extracted from the plant Stephania Tetrahydropalmatine L-body, also known as Rotundine or tetrahydropalmatine, palmatine (e.g. L-tetrahydropalmatine, L-THP), an
  • Rotundine can be used alone or added to all the formulations in the current invention for PE in effective therapeutical amount (e.g. lOmg ⁇ 200mg) to increase their potency in increasing ejaculation latency.
  • effective therapeutical amount e.g. lOmg ⁇ 200mg
  • the combination of rotundine with SSRIs e.g. those used in the previous examples
  • Rotundine can cause user feel sleepy.
  • antagonize hypnotic effect e.g. Caffeine 10mg ⁇ lOOmg and/or Taurine 300mg ⁇ lOOOmg
  • Caffeine 10mg ⁇ lOOmg and/or Taurine 300mg ⁇ lOOOmg can be added to the formulation.
  • rotundine can be co-formulated with antidepressant to treat depression and increase ejaculation latency.
  • antidepressant for example, rotundine can be co-formulated with antidepressant to treat depression and increase ejaculation latency.
  • suitable amount of antidepressant used in the formulation is Paroxetine 2.5-30 mg, Sertraline 5-100 mg, escitalopram l-20mg, citalopram 2- 40 mg,
  • a volunteer took a capsule containing 10 mg of escitalopram, 50 mg of rotundine with optional 20-100mg caffeine and optional 100- 500mg taurine 1-2 hours before sex. In another embodiment, a volunteer took a capsule
  • a volunteer took a capsule containing 5 mg of paroxetine, 500 mg of curcumin and 60 mg of rotundine 2 hrs before sex. In one embodiment, a volunteer took a capsule containing 5 mg of escitalopram, 500 mg of curcumin, 5 Omg caffeine and 30 mg of rotundine 2 hrs before sex. In one embodiment, a volunteer took a capsule containing 500 mg of curcumin 365 and 100 mg of rotundine 2 hrs before sex.
  • a volunteer took a capsule containing 5 mg of escitalopram, 500 mg of curcumin and 30 mg of rotundine 1 or 2 hrs before sex.
  • escitalopram 500 mg of curcumin
  • 30 mg of rotundine 1 or 2 hrs before sex.
  • Natural antidepressant such as St. John's wort extract or its active components such as hyperforin can also be used in combination with rotundine.
  • a volunteer took a capsule containing 10-50 mg of hyperforin and 30-90 mg of rotundine and 30mg caffeine with optional 500mg taurine 1 or 2 hrs before sex to increase ejaculation latency.
  • the inventor discovered that using rotundine alone (e.g. taken orally 50- 200 mg 1 hr before sex) can also increase ejaculation latency, but using it in combination with SSRI or curcumin increases its efficacy.
  • PDE5 inhibitor drugs e.g. sildenafil
  • sildenafil can also be added to the
  • oral formulations such as tablet or capsule.
  • Melatonin e.g. 1- 20mg
  • Melatonin can also be used instead of rotundine or be used together with above formulations.
  • Corydalis genus such as Rhizoma Corydalis (Corydalis yanhusuo) extract (e.g. 500- 10000 mg such as 5: 1 extract using water/ethanol extraction) or Stephania rotunda extract
  • Rhizoma Corydalis extract contain alkaloids including corydaline, dl-Tetrahydropalmatine, protopine, L- tetrahydropalmatine, dl-Tetrahydrocladus Alkaloids, L-tetrahydrocannabinol, beta-high- celandine, coptisine, corynebacterium, corydalis, berberine, Tetrahydropalmatine Tetrandrine,
  • DHCB alkaloid dehydrocorybulbine
  • Tetrahydrocolumbamine Corydalis H, Corydalis I, Corydalis J, Corydalis K, Corydalis L, a- Allocryptopine, Dehydrocorydaline, d-Corybulbine, Dehydrocorydalmine, Corydalmine, Corypalmine, N-methyltetrahydrocolumbamine, N-methyltetrahydrocoptisine and Norisocorydin. These compounds have similar effect and can be used as purified form or their combination for
  • THPB tetrahydroprotoberberines
  • levostepholidine levostepholidine
  • L-scoulerine levostepholidine
  • D,L-govadine tetrahydroprotoberberines
  • the dosage of the compound listed above or their combination used for the current invention is between 30mg - 3000 mg.
  • a volunteer took 5 capsules containing totally 1000 mg of Rhizoma
  • a volunteer took 2 capsules containing totally 1000 mg of Rhizoma Corydalis extract (10 : 1 concentrate granule, equals to 50g bulk herb) and 20mg caffeine 0.5-2 hrs before sex.
  • a volunteer took 2 capsules containing totally 1000 mg of Rhizoma Corydalis extract (10 : 1
  • a volunteer took 50mL liquid formulation contains 100 mg of rotundine and 100 mg dehydrocorybulbine (DHCB) 2 hrs before sex.
  • the capsules can contains additional curcumin or the like as described previously.
  • a volunteer took 2 capsules containing totally 1000 mg of Rhizoma Corydalis extract (10 : 1 concentrate granule, equals to
  • a volunteer took 50mL liquid formulation contains 100 mg of rotundine and 100 mg dehydrocorybulbine (DHCB) and 30mg of hyperforin and 30mg adhyperforin 0.5- 2 hrs before sex.
  • DHCB dehydrocorybulbine
  • a volunteer took a capsule containing 500 mg of curcumin and 60 mg of rotundine
  • DHCB dehydrocorybulbine
  • All these formulation can cause delayed ejaculation.
  • Extract from danshen root, Panax notoginseng, Radix Angelicae Dahuricae, Rhizoma Cyperi Rotundi, Rhizoma and Ligustici Chuanxiong can also be added to the formulation (e.g. extract equals to 25g of bulk herb).
  • the active compound from these extract e.g. 500mg coumarin of angelicae dahuricae
  • dopamine receptor antagonist in effective therapeutical amount to increase their potency in increasing ejaculation latency.
  • dopamine antagonist with SSRIs can provide better delaying ejaculation effect than using them alone.
  • suitable dopamine antagonist include Chlorpromazine,
  • the dopamine antagonist can be dopamine
  • D3 receptor antagonist such as BP897, CAM89, NGB2904, NGB2849, PG619, CJB090, YQA14, PG01037, RGH188/canprazine, PG622, FAUC365, ST-198, SB-269652, SB-277011A, SB- 414796, R-PG648, PG01037, ABT-925, SR21502, GSK598809, GSK618334, BAK2-66, Buspirone, S33084 and S33138. They can be given to the person in need as an oral formulation
  • the amount used in the formulation to delay ejaculation generally is less than the amount (e.g. 20% -90) of that used in clinics for other indication using dopamine antagonist.
  • a person in need can take 50mg GSK598809 or GSK618334 1-2 hrs before sex to
  • a person in need can take 30mg GSK598809 and 1000 mg 2 hrs before sex. In another example, a person in need can take 30mg GSK598809 and 100 mg L-tetrahydropalmatine lhr before sex. In another example, a person in need can take 30mg GSK598809 and 100 mg L-tetrahydropalmatine and 30mg caffeinelhr before sex. In another example, a person in need can take 30mg GSK598809 and 10 mg escitalopram l-2hrs before sex.
  • a person in need can take 30mg GSK598809 and 500 mg curcumin l-2hrs before sex. In another example, a person in need can take 30mg GSK598809 and 20 mg hyperforin l-2hrs before sex. In another example, a person in need can take 5mg Buspirone and 10 mg escitalopram l-2hrs before sex. In another embodiment, a person in need can take 3mg Cariprazinel-2 hrs before sex to delay ejaculation; in another embodiment, a person in need can
  • 440 take 2 mg Cariprazine and 1000 mg 2 hrs before sex.
  • a person in need can take 3mg Cariprazine and 100 mg L-tetrahydropalmatine lhr before sex.
  • a person in need can take 3mg Cariprazine and 100 mg L-tetrahydropalmatine lhr before sex.
  • a person in need can take 3mg Cariprazine and 10 mg escitalopram l-2hrs before sex.
  • a person in need can take 30mg Cariprazine and 500 mg
  • curcumin l-2hrs before sex 445 curcumin l-2hrs before sex.
  • a person in need can take 3mg Cariprazine and 20 mg hyperforin 1 -2hrs before sex.
  • the dosage form used for the current invention is an orally taken formulation such as capsule, liquid capsule, tablet, lozenge, emulsion, solution and etc, which contains
  • active ingredient and pharmaceutically acceptable excipients 450 such as starch, cellulose, gelatin and etc, which is well known to the skilled in the art.
  • pharmaceutically acceptable excipients 450 such as starch, cellulose, gelatin and etc, which is well known to the skilled in the art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides compositions and methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition to a human male on an as-needed basis shortly before sexual activity to delay ejaculation.

Description

THERAPEUTICAL METHODS, FORMULATIONS AND NUTRACEUTICAL
FORMULATIONS
CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62/427,816 filed on November 30, 2016, which is a Continuation-In-Part application of U.S. Patent Application No. 14/824,078 filed on August 12, 2015. The entire disclosure of the prior application is considered to be part of the disclosure of the instant application and is hereby incorporated by reference.
BACKGROUND OF THE INVENTION Field of the Invention
The invention relates to methods and compositions of delaying ejaculation. In particular, the invention relates to a method of delaying ejaculation by the administration of a tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition. The compositions can also be used to treat depression. Background Information
Premature ejaculation is a debilitating sexual dysfunction. This dysfunction can lead to an inability to enter into, or sustain, relationships and can cause psychological damage to sufferers. Premature ejaculation can also impair reproductive success. Treatments for premature ejaculation include psychological therapies, topical anesthetics, and the use of devices. All of these treatments have significant drawbacks. Psychological therapies benefit only a subset of patients and require specialized therapists who may not be available to all patients. Furthermore, psychological therapies cannot alleviate premature ejaculation resulting from non-psychological causes. Anesthetic agents decrease sensitivity of tissues, thereby diminishing sexual pleasure. Also, topical anesthetics can be transferred to sexual partners and thereby decrease their sensitivity and pleasure as well. With regard to devices, these can be awkward, inconvenient and embarrassing to use. Devices are highly conspicuous and reveal the very condition which the suffering partner may prefer to conceal. Additionally, devices can cause irritation to one or both partners. Methods for treating premature ejaculation by systemic administration of fluoxetine, sertraline, Paroxetine, Dapoxetine and tramadol have been described. However, these drugs may not be effective for all patients, and their side effects can halt treatment or impair patient compliance. Disease states or adverse interactions with other drugs may contraindicate the use of these compounds or require lower dosages that may not be effective to delay the onset of ejaculation.
DESCRIPTION OF THE INVENTIONS AND THE PREFERRED EMBODIMENT The current invention discloses methods, reagents and pharmaceutical formulations to treat PE (premature ejaculation) or increase the pre-ejaculation time during sexual activity. It also discloses methods, reagents and pharmaceutical formulations to treat erectile dysfunction, cancer, and depression.
One aspect of the current invention provides a low side effect, rapid onset composition to treat premature ejaculation or increase the pre-ejaculation time during sexual activity. It also provide a method to treat premature ejaculation or increase the pre ejaculation time during sexual activity by taking the said formulation orally within 10 hours before intercourse. One example of a preferred composition contains l~20mg of escitalopram or 20-100mg hyperforin, and/or 100- lOOOmg Rhizoma Corydalis extract and 50- 2000mg of curcumin or curcumin salt (e.g.
curcumin sodium salt) or curcumin derivative. Optionally it can further contains 1-20 mg of piperine or turmeric oil. Suitable dosage forms include capsule, liquid capsule, tablet, lozenge, liquid gel, solution (e.g. in 50% ethanol solution) and etc.
The formulation contains one or more antidepressant selected form natural or synthetic SNRI or SSRIs or agomelatine (Valdoxan). The suitable amount of drug used in the formulation is 5% -100% dosage amount of the amount used as antidepressants. Synthetic SNRI is serotonin and norepinephrine reuptake inhibitor, such as venlafaxine, duloxetine. SSRIs are selective serotonin reuptake inhibitors that are generally used antidepressants. Examples of synthetic SSRIs include fluoxetine (Prozac), paroxetine (Paxil), and sertraline (Zoloft), dapoxetine, escitalopram and citalopram. The formulation also contains curcuminoid polyphenol (curcumin type compound). The suitable amount of curcuminoid used in the formulation is between 20mg-2000mg.
Suitable curcumin type compound can be either pure curcumin (diferuloylmethane) or curcuminoid mixture (e.g. that extracted from turmeric, contains approximately 70-80% diferuloylmethane, 10-20% demethoxy cur cumin, and 5-10% bisdemethoxy cur cumin) or curcumin derivatives. The pure curcumin (diferuloylmethane) performs similar as curcuminoid extracted from turmeric. The terms curcumin, turmeric extract and curcuminoid are used interchangeable in the current invention.
Optionally the composition can further contain 1-20 mg of piperine or chavicine. Piperine, along with its isomer chavicine, is the alkaloid responsible for the pungency of black pepper and long pepper. Optionally turmeric oil (turmerne) can also be added to improve bioavailability of curcumin. One example is Biocurcumax (curcumin mixed with turmeric oil). Optionally it can further contain caffeine 20~200mg. Optionally it can further contain cGMP-specific
phosphodiesterase (PDE5) inhibitor. The suitable dose of PDE5 inhibitor is 20% -150% dosage amount of the amount used in treating erectile dysfunction. Bile acid, chitin or none ionic surfactant such as Poloxamer or Tween (e.g. tween-80) can be added to the formulation to improve the absorption of the drug.
Example of suitable PDE5 inhibitor can be selected from avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, zaprinast and icariin. Sildenafil can be added to the formulation at the amount between 10- 1 OOmg. Tadalafil can be added to the formulation at the amount between lmg- 20 mg. Vardenafil can be added to the formulation at the amount between 1 mg- 20 mg.
Suitable amount of antidepressant used in the formulation is Paroxetine 2.5-30 mg, Sertraline 5- 100 mg, escitalopram l-20mg, citalopram 2- 40 mg, dapoxetine 5-60mg, fluoxetine 5-80mg , Venlafaxine 5-30mg, duloxetine 5-60mg. In one embodiment, a volunteer took a capsule containing 10 mg of escitalopram, 500 mg of curcuminoid. After 3 hours, the pre ejaculation time was 30 minutes compared with 10 minutes previously without the drug. After 20 hours, the pre ejaculation time was 20 minutes compared with 10 minutes previously without the drug.
In another embodiment, a volunteer took 10ml 50% ethanol aqueous solution containing 10 mg 85 Escitalopram and 500 mg of curcumin in the form of curcuminoid extract from turmeric. After 1.5 hours, the pre ejaculation time was 30 minutes compared with 10 minutes previously without the drug. After 20 hours, the pre ejaculation time was 20 minutes compared with 10 minutes previously without the drug. In another embodiment, a volunteer took a capsule containing 5 mg of escitalopram, 300 mg of curcuminoid extract from turmeric and 2 mg of piperine. After 3 90 hours, the pre-ejaculation time was 20 minutes compared with 5 minutes without the drug
previously. After 20 hours, the pre- ejaculation time was 20 minutes compared with 5 minutes previously without the drug.
In another embodiment, a volunteer took 5ml 50% ethanol aqueous solution containing 5 mg of escitalopram, 300 mg of curcumin and 2 mg of piperine. After 1.5 hours, the pre ejaculation time 95 was 20 minutes compared with 5 minutes without the drug previously. After 20 hours, the pre ejaculation time was 20 minutes compared with 5 minutes previously without the drug.
In another embodiment, a volunteer took a capsule containing 10 mg of citalopram, 500 mg of curcumin and 2 mg of piperine. After 3 hours, the pre ejaculation time was 20 minutes compared with 5 minutes without the drug previously. In another embodiment, a volunteer took a capsule 100 containing 1 mg of citalopram, 500 mg of curcumin and 2 mg of piperine. After 3 hours, the pre ejaculation time was 15 minutes compared with 5 minutes without the drug previously. The volunteer also reported improved erection.
It is known that many antidepressants can reduce sex drive and further cause erection dysfunction. The addition of curcuminoid can reduce these side effects and further improve 105 erection.
In another embodiment, a volunteer took a capsule containing 3 mg of escitalopram, 200 mg of curcumin and 30 mg of sildenafil. After 2 hours, the pre ejaculation time was 20 minutes compared with 5 minutes without the drug previously. The volunteer also reported improved erection. 110 In another embodiment, the formulation is a liquid form contains 5ml 50% ethanol, 5 mg of escitalopram, 20mg caffeine, 250 mg of curcumin and 5mg of vardenafil. The liquid can be taken by the person in need before sexual activity.
In another embodiment, the formulation is a liquid capsule contains 5 mg of escitalopram, 200 mg of curcumin and 30 mg of sildenafil in 50% glycerol, 20% ethanol solution. The capsule can 115 be taken by the person in need 3 hours before the sexual activity.
When volunteers took 20mg of escitalopram only once orally, significant side effects were observed (stomach irritation, nausea and headache) and no significant changes in pre ejaculation time were observed after 3 hours. When same volunteers took a capsule containing lOmg of escitalopram + curcumin 500mg once, much lower side effects were observed and significant
120 increases in pre ejaculation time were observed after 3 hours. When same volunteers took a
capsule containing 5mg of escitalopram + curcumin 500mg + 2 mg of piperine once, no side effects were observed and significant increase in pre ejaculation time were observed after 3 hours comparable to lOmg of escitalopram + curcumin 500mg. When the same volunteers took a capsule containing curcumin 500mg or curcumin 500mg + 2 mg of piperine, no significant
125 changes in pre ejaculation time were observed after 1 hours, 3 hours and 12 hours.
In one embodiment, in repeated experiments a volunteer took a capsule containing 10 mg of paroxetine, 500 mg of curcumin. After 3 hours, the average pre ejaculation time was 25 minutes compared with 10 minutes previously without the drug. The volunteer reported slight side effects (mild nausea).
130 In one embodiment, in repeated experiments a volunteer took a capsule containing 5 mg of
paroxetine, 500 mg of curcumin. After 3 hours, the average pre ejaculation time was 15 minutes compared with 10 minutes previously without the drug. The volunteer reported very slight side effects (very mild nausea).
In another embodiment, in repeated experiments a volunteer took a capsule containing 5 mg of 135 paroxetine, 300 mg of curcumin and 2 mg of piperine. After 3 hours, the average pre ejaculation time was 15 minutes compared with 5 minutes without the drug previously. The volunteer reported no significant side effects. In repeated experiments the same volunteer took a capsule containing 30 mg of paroxetine only and the average pre ejaculation time was 8 minutes after 3 hours compared with 5 minutes without the drug previously. However the volunteer reported 140 significant side effects (stomach irritation, nausea and headache).
In one embodiment, in repeated experiments a volunteer took a capsule containing 20 mg of dapoxetine, 500 mg of curcumin. After 3 hours, the average pre ejaculation time was 20 minutes compared with 10 minutes previously without the drug. The volunteer reported slight side effects (mild nausea).
145 In another embodiment, in repeated experiments a volunteer took a capsule containing 15 mg of dapoxetine, 300 mg of curcumin and 2 mg of piperine. After 3 hours, the average pre ejaculation time was 20 minutes compared with 5 minutes without the drug previously. The volunteer reported no significant side effects. In repeated experiments the same volunteer took a capsule containing 60 mg of dapoxetine only and the average pre ejaculation time was 20 minutes after 3
150 hours compared with 5 minutes without the drug previously. However the volunteer reported significant side effects (stomach irritation, nausea and headache).
In one embodiment, in repeated experiments a volunteer took a capsule containing 30 mg of sertraline, 500 mg of curcumin. After 3 hours, the average pre ejaculation time was 15 minutes compared with 5 minutes previously without the drug. The volunteer reported slight side effects 155 (mild nausea). In repeated experiments the same volunteer took a capsule containing 60 mg of sertraline only and no significant increase in pre-ejaculation time was observed after 3 hours; and the volunteer reported significant side effects (stomach irritation, nausea and headache). Only after taking the 60 mg of sertraline once daily for 10 days continuously, the average pre ejaculation time was 10 minutes compared with 5 minutes previously without the drug.
160 In one embodiment, in repeated experiments a volunteer took a capsule containing 30 mg of duloxetine, 500 mg of curcumin. After 3 hours, the average pre ejaculation time was 10 minutes compared with 5 minutes previously without the drug. The volunteer reported slight side effects (mild nausea). In repeated experiments the same volunteer took a capsule containing 60 mg of duloxetine only and no significant increase in pre-ejaculation time was observed after 3 hours;
165 and the volunteer reported significant side effects (stomach irritation, nausea and headache). Alternatively, the antidepressant in the above embodiments used can be natural product or natural product extract instead of synthetic SSRI. Preferably the natural antidepressant is St. John's wort extract such as those commercially available as nutraceuticals and medicines used for mood improvement. The preferred dosage of St. John's wort extract used is between
170 300mg~3000mg. Preferably the St. John's wort extract contains at least 3% hypericin,
adhyperforin, pseudohypericin, and hyperforin combined weight. In one embodiment, in repeated experiments a volunteer took 1 capsule containing 1000 mg of St. John's wort extract and one capsule containing 1000 mg of curcumin and 5mg of piperine. After 2 hours, the average pre ejaculation time was 15 minutes compared with 5 minutes previously without the drug. The
175 volunteer reported no side effects. In one embodiment, in repeated experiments a volunteer took 2 capsules each containing 1000 mg of St. John's wort extract and one capsule containing 1000 mg of curcumin and 5mg of piperine. After 2 hours, the average pre ejaculation time was 20 minutes compared with 5 minutes previously without the drug. The volunteer reported no side effects. In one embodiment, in repeated experiments a volunteer took a mixture of powder
180 containing 1000 mg of St. John's wort extract, 1000 mg of curcumin and 5mg of piperine. After 2 hours, the average pre ejaculation time was 20 minutes compared with 5 minutes previously without the drug. The commercially available St. John's wort extract contains low amount of hypericin, pseudohypericin, and hyperforin, it can be further concentrated to contain higher amount of hypericin, pseudohypericin, and hyperforin to reduce the amount of drug used
185 accordingly. Furthermore, Morinda officinalis (Medicinal Indianmulberry Root) extract
(100mg~1000mg) can also be added to the formulation.
The main active agents in St. John's wort extract are hypericin, adhyperforin, pseudohypericin and hyperforin which can be oxidized readily therefore show reduced potency. Curcuminoid is potent antioxidant which protect the active agents in St. John's wort extract from being oxidized 190 therefore improve their potency when being co-formulated and taken together. This is one of the mechanisms that curcuminoid plus St. John's wort extract shows better therapeutical efficacy than using St. John's wort extract alone. Curcuminoid has low bioavailability and most of them keep intact in gastrointestinal (GI) tract, therefore can protect the drug from being oxidized for a longer time in GI tract than other antioxidant that can be absorbed in GI tract readily. 195 Curcuminoid can also be added to the formulation for other drugs to protect them from being oxidized and increase their potency.
Among hypericin, pseudohypericin and hyperforin in St. John's wort extract, adhyperforin and hyperforin are most potent active substances. Preferably the composition in the current invention contains 5-100 mg hyperforin or adhyperforin or their combination. Most preferably the
200 composition in the current invention contains 10-50 mg hyperforin or adhyperforin or their
combination. In one embodiment, in repeated experiments a volunteer took 1 capsule containing 10 mg of hyperforin from concentrated St. John's wort extract, 500 mg of cur cumin and 5mg of piperine. After 2 hours, the average pre ejaculation time was 10 minutes compared with 5 minutes previously without the drug. The volunteer reported no side effects and reported better
205 erection. In another embodiment, a volunteer took 1 capsule containing 10 mg of hyperforin only and after 2 hours the average pre ejaculation time was not changed compared to the time previously without the drug. In another embodiment, in repeated experiments a volunteer took 1 capsule containing 20 mg of mixture of hyperforin and adhyperforin, and 500 mg of curcumin. After 2 hours, the average pre ejaculation time was 15 minutes compared with 5 minutes
210 previously without the drug. The volunteer reported no side effects. In another embodiment, in repeated tests a volunteer took 1 capsule containing 30 mg of hyperforin only. After 2 hours, the average pre ejaculation time was slightly increased to around 8 minutes compared with 5 minutes previously without the drug. However, headache was reported.
Alternatively, hyperforin in the above embodiments can be replaced with hyperforin
215 derivatives/analogues such as those disclosed in Patent US7105705 and Patent US9321713.
Hyperforin derivatives/analogues (e.g. orally taken 10- lOOmg) can also increase the pre ejaculation time either used alone or in combination with curcumin. The formulation containing both curcumin and hyperforin derivatives/analogues has better efficacy than using hyperforin derivatives/analogues alone.
220
Alternatively, Centella asiatica extract can be used alone or added to other embodiments in the current invention to increase the pre ejaculation time and treat depression. Centella asiatica extract's active component contains Centella triterpenic genine, Asiaticoside, Madecassoside, Asiatic & Madecassic acid. Preferably the composition in the current invention as oral
225 formulation contains 100-5000 mg Centella triterpenic genine or Asiaticoside or Madecassoside or Asiatic or Madecassic acid or their combination. In another embodiment, a volunteer took 1 capsule containing 2000 mg of Centella triterpenic genine and after 2 hours the average pre ejaculation time was 10 minutes compared with 5 minutes previously without the drug. In another embodiment, a volunteer took 2000 mg of Centella triterpenic genine, 30mg hyperforin
230 and 500 mg of curcumin , and after 2 hours the average pre ejaculation time was 15 minutes
compared with 5 minutes previously without the drug.
Alternatively, Tramadol can be used in all the above embodiments. When Tramadol is used, antidepressant (e.g. synthetic SSRI or St. John's wort extract) can be omitted or the curcumin can be omitted from the formulation although the combination of all three is also effective. The term
235 "tramadol" is used herein to refer to 2-[(dimethylamino)methyl]-l-(3-methoxyphenyl)- cyclohexanol ("tramadol") and all pharmaceutically-acceptable forms and derivatives of tramadol. In particular, the term includes the N-oxide derivative ("tramadol N-oxide") and the O- desmethyl derivative ("O-desmethyl tramadol"). The term also includes the solvates, polymorphs, and pharmaceutically-acceptable acid addition salts of tramadol and its derivatives. The term
240 further includes all of the stereoisomers of any of the foregoing, including individual
stereoisomers (including individual enantiomers) and mixtures of stereoisomers (including the racemates). Preferred dosage is between 5mg~50mg.
In one embodiment, in repeated experiments a volunteer took a capsule containing 10 mg of paroxetine, 20 mg of Tramadol. After 3 hours, the average pre ejaculation time was 25 minutes 245 compared with 5 minutes previously without the drug. The volunteer reported slight side effects (mild nausea).
In another embodiment, in repeated experiments a volunteer took a capsule containing 3 mg of escitalopram, 20 mg of Tramadol. After 3 hours, the average pre ejaculation time was 25 minutes compared with 5 minutes previously without the drug. The volunteer reported no side effects. 250 While 20 mg of Tramadol only increase the average pre ejaculation time to lOmin. In another embodiment, in repeated experiments a volunteer took a capsule containing 500 mg of curcumin, 2mg of piperine, 20 mg of Tramadol. After 3 hours, the average pre ejaculation time was 25 minutes compared with 5 minutes previously without the drug. The volunteer reported no side effects.
255 In one embodiment, in repeated experiments a volunteer took a capsule containing 500 mg of curcumin, 2mg of escitalopram, 10 mg of Tramadol. After 3 hours, the average pre ejaculation time was 25 minutes compared with 5 minutes previously without the drug. The volunteer reported no side effects.
The current invention disclosed that curcuminoid can be co-formulated together or be
260 administered together with other drugs having ejaculation delaying effect to further improve their ejaculation delaying effect, reduce drug dose and reduce side effect. Besides the drugs listed above, other drugs or agents having ejaculation delaying effect can also be used in combination with curcuminoid to boost their efficacy and reduce their side effect and dose. Examples of these agents include but are not limited to morphine and morphine derivatives (e.g. those disclosed in 265 US patent 8,158,764), Delta opioid receptor agonist (e.g. those disclosed in US patent application 11/696,806) and certain serotonin agonists and antagonists (e.g. those disclosed in U.S. Patent 6,037,360).
The current invention also provides method and formulations containing curcumin and St. John's wort extract to treat depression. The preferred dosage of St. John's wort extract used is between
270 300mg~3000mg. The preferred dosage of curcumin extract used is between 300mg~3000mg. A patient suffering depression took one capsule three times daily and each capsule contains St. John's wort extract 300mg and curcumin 500mg. After two weeks, the patient report much improved mood and no side effects were observed. Piperine 2-20mg can also be added to the formulation. Morinda officinalis (Medicinal Indianmulberry Root) extract (100mg~1000mg) can
275 also be added to the formulation.
The current invention also provides method and formulations containing curcumin and escitalopram to treat depression. The preferred dosage of curcumin used is between
300mg~3000mg. The preferred dosage of escitalopram used is between 5mg~10mg. A patient suffering depression took one capsule daily and each capsule contains escitalopram 5mg and 280 curcumin 500mg. After two weeks, the patient report much improved mood comparable to
taking escitalopram lOmg daily and no side effects were observed. Piperine 2-20mg can also be added to the formulation.
The current invention also provides method and formulations containing escitalopram and St. John's wort extract to treat depression. The preferred dosage of St. John's wort extract used is
285 between 300mg~3000mg. The preferred dosage of escitalopram used is between 5mg~10mg. A patient suffering depression two capsules daily and each capsule contains St. John's wort extract 300mg and escitalopram 5mg. After one weeks, the patient report much improved mood comparable to taking escitalopram 20mg daily. Curcumin 200-500mg and Piperine 2-20mg can also be added to each capsule. Furthermore, Morinda officinalis (Medicinal Indianmulberry
290 Root) extract (100mg~1000mg) can also be added to the formulation.
In the above methods and formulations to treat depression, the SSRI can be replaced with one synthetic SNRI such as venlafaxine and duloxetine or Valdoxan. The amount of SNRI or Valdoxan used in the formulation can be lower than they being used alone. Normally half daily dose is enough to reach the desired effect.
295 The current invention also provides formulations containing curcumin as injection dosage to treat diseases such as cancer or Alzheimer. It contains curcumin solid lipid nanoparticles, which can be made by a microemulsion technique such as using microfluidizer at suitable temperature (e.g. at 25-75 degrees C). It contains curcumin 0.1%-10%, lecithin (e.g. from soybean or egg) 0.2% - 20%, optionally surfactant %1 -10%, carbohydate such as lactose, glucose, sugar l%-20% and
300 water and pH adjusting reagent such as PBS. The mixture can be further lyophilized to improve long term storage stability. When injected to the patient, it provides better bioavailability and better therapeutical effects.
The composition containing both curcumin and St. John's wort extract or composition containing both curcumin and hyperforin can be used for Alzheimer treatment. For example, a capsule 305 containing 500mg curcumin, Piperine 2 mg and 500 mg St. John's wort extract can be taken
orally 3 times a day to treat Alzheimer. In another example, a capsule containing 500mg curcumin and 30 mg tetrahydrohyperforin can be taken orally 2 times a day to treat Alzheimer. In another example, a capsule containing 500mg curcumin and 30 mg hyperforin can be taken orally 2 times a day to treat Alzheimer. They can be also be made in injection form to treat
310 Alzheimer.
The current invention also provides a formulation containing curcumin and cordycepin to treat cancer or reduce the side effect of radio/chemotherapy. Preferred curcumin amount is between 300mg-3g, and the preferred amount of cordycepin is between 5-100 mg. The cordycepin can be in the form of Cordyceps sinensis extract, Cordyceps militaris extract or those from fermentation 315 as well as synthetic cordycepin. In one embodiment, the formulation is a capsule or tablet
contains 500mg of curcumin, 5 mg of piperine and 20mg of synthetic cordycepin (or 500mg of Cordyceps militaris extract which contains 3% cordycepin). A patient takes it three times a day for cancer treatment.
The current invention also provides a formulation containing curcumin and epimedium
320 brevicornu (Horny Goat Weed) extract to treat erectile dysfunction. Preferred curcumin amount is between 300mg-lg, and the preferred amount of Epimedium brevicornu extract is between lOOmg-lg, which can be made from 3-20g dry Epimedium brevicornu. In one embodiment, the formulation is a capsule or tablet contains 500mg of curcumin, 500mg of Epimedium brevicornu exatrct standardized to contain 10% icariin. Furthermore Maca Extract 75 mg -300mg can also 325 be incorporated to the formulation. A volunteer took one capsule 3 hours before intercourse showed improved erection and slightly increased ejaculation latency. St. John's wort extract 300mg~1000 mg can also be added to the capsule/tablet to further increase the ejaculation latency time.
In all the above inventions, suitable curcumin type compound can be either turmeric extract, 330 curcumin (diferuloylmethane) or curcuminoid (e.g. that extracted from turmeric, contains
approximately 70-80% diferuloylmethane, 10-20% demethoxy curcumin, and 5-10%
bisdemethoxy curcumin) or one or more selected from natural curcumin derivatives including curcumin metabolites including tetrahydrocurcuminoids (e.g. curcumin glucuronide, curcumin sulfate, tetrahydrocurcumin, and hexahydrocurcumin) or synthetic curcumin derivatives such as 335 curcumin mono or di glycoside, curcumin mono or di carboxylic acid ester, curcumin mono or di phosphate. The curcumin (diferuloylmethane) and tetrahydrocurcumin performs similar as curcuminoid extracted from turmeric. Curcumin can be in the form of one or more
curcuminoid/curcumin derivatives in complex with micelles, emulsion, nanoparticles, liposome and cyclodextrin such as alpha or beta-cyclodextrin or hydroxypropyl-y-cyclodextrin and
340 hydroxypropyl-beta-cyclodextrin. Optionally it can further contains 1-20 mg of piperine or lmg- 200mg turmeric oil. The above natural products based formulations can be used as nutraceuticals without being approved as drugs.
Rotundine (rotundine) is extracted from the plant Stephania Tetrahydropalmatine L-body, also known as Rotundine or tetrahydropalmatine, palmatine (e.g. L-tetrahydropalmatine, L-THP), an
345 analgesic. It can also be chemically synthesized. Rotundine can be used alone or added to all the formulations in the current invention for PE in effective therapeutical amount (e.g. lOmg ~ 200mg) to increase their potency in increasing ejaculation latency. The combination of rotundine with SSRIs (e.g. those used in the previous examples) can provide better delaying ejaculation effect than using them alone. Rotundine can cause user feel sleepy. A medicine that can
350 antagonize hypnotic effect (e.g. Caffeine 10mg~ lOOmg and/or Taurine 300mg~ lOOOmg) can be added to the formulation.
For example, rotundine can be co-formulated with antidepressant to treat depression and increase ejaculation latency. Example of suitable amount of antidepressant used in the formulation is Paroxetine 2.5-30 mg, Sertraline 5-100 mg, escitalopram l-20mg, citalopram 2- 40 mg,
355 dapoxetine 5-60mg, fluoxetine 5-80mg , Venlafaxine 5-3 Omg, duloxetine 5-60mg. Example of suitable amount of rotundine is between 10 ~ 500 mg, preferably between 20 ~ 200 mg; for example, 30 mg or 60mg or 120mg. In one embodiment, a volunteer took a capsule containing 10 mg of escitalopram, 50 mg of rotundine with optional 20-100mg caffeine and optional 100- 500mg taurine 1-2 hours before sex. In another embodiment, a volunteer took a capsule
360 containing 10 mg of paroxetine, 30 mg of rotundine and 10 mg of caffeine 2 hours before sex. In one embodiment, a volunteer took a capsule containing 5 mg of paroxetine, 500 mg of curcumin and 60 mg of rotundine 2 hrs before sex. In one embodiment, a volunteer took a capsule containing 5 mg of escitalopram, 500 mg of curcumin, 5 Omg caffeine and 30 mg of rotundine 2 hrs before sex. In one embodiment, a volunteer took a capsule containing 500 mg of curcumin 365 and 100 mg of rotundine 2 hrs before sex. In one embodiment, a volunteer took a capsule containing 5 mg of escitalopram, 500 mg of curcumin and 30 mg of rotundine 1 or 2 hrs before sex. Using the above combinations showed better efficacy in increasing ejaculation latency than using SSRI alone or rotundine alone. Natural antidepressant such as St. John's wort extract or its active components such as hyperforin can also be used in combination with rotundine. In one
370 embodiment, a volunteer took a capsule containing 10-50 mg of hyperforin and 30-90 mg of rotundine and 30mg caffeine with optional 500mg taurine 1 or 2 hrs before sex to increase ejaculation latency. The inventor discovered that using rotundine alone (e.g. taken orally 50- 200 mg 1 hr before sex) can also increase ejaculation latency, but using it in combination with SSRI or curcumin increases its efficacy. PDE5 inhibitor drugs (e.g. sildenafil) can also be added to the
375 oral formulations such as tablet or capsule.
Alternatively, Melatonin (e.g. 1- 20mg) can also be used instead of rotundine or be used together with above formulations.
Alternatively, Corydalis genus such as Rhizoma Corydalis (Corydalis yanhusuo) extract (e.g. 500- 10000 mg such as 5: 1 extract using water/ethanol extraction) or Stephania rotunda extract
380 can also be used instead of rotundine in the above embodiments to increase pre ejaculation time or to treat depression alone or in combination with curcumin. The active ingredients of Rhizoma Corydalis extract contain alkaloids including corydaline, dl-Tetrahydropalmatine, protopine, L- tetrahydropalmatine, dl-Tetrahydrocladus Alkaloids, L-tetrahydrocannabinol, beta-high- celandine, coptisine, corynebacterium, corydalis, berberine, Tetrahydropalmatine Tetrandrine,
385 alkaloid dehydrocorybulbine (DHCB), alkaloids glaucine, palmatine, d-Corydaline,
Tetrahydrocolumbamine, Corydalis H, Corydalis I, Corydalis J, Corydalis K, Corydalis L, a- Allocryptopine, Dehydrocorydaline, d-Corybulbine, Dehydrocorydalmine, Corydalmine, Corypalmine, N-methyltetrahydrocolumbamine, N-methyltetrahydrocoptisine and Norisocorydin. These compounds have similar effect and can be used as purified form or their combination for
390 the current invention. Other tetrahydroprotoberberines (THPB) such as levostepholidine,l- scoulerine and D,L-govadine can also be used in the current invention. Preferably the dosage of the compound listed above or their combination used for the current invention is between 30mg - 3000 mg. In one embodiment, a volunteer took 5 capsules containing totally 1000 mg of Rhizoma
395 Corydalis extract (10 : 1 concentrate granule, equals to 50g bulk herb) with optional 20-100mg caffeine and optional 100-500mg taurine 0.5-2 hrs before sex. In one embodiment, a volunteer took 2 capsules containing totally 1000 mg of Rhizoma Corydalis extract (10 : 1 concentrate granule, equals to 50g bulk herb) and 20mg caffeine 0.5-2 hrs before sex. In one embodiment, a volunteer took 2 capsules containing totally 1000 mg of Rhizoma Corydalis extract (10 : 1
400 concentrate granule, equals to 50g bulk herb) and 500mg St. John's wort extract 0.5- 2 hrs before sex. In one embodiment, a volunteer took 50mL liquid formulation contains 100 mg of rotundine and 100 mg dehydrocorybulbine (DHCB) 2 hrs before sex. The capsules can contains additional curcumin or the like as described previously. In one embodiment, a volunteer took 2 capsules containing totally 1000 mg of Rhizoma Corydalis extract (10 : 1 concentrate granule, equals to
405 50g bulk herb) and 500mg St. John's wort extract and 500mg curcumin with optional 20-1 OOmg caffeine and optional 100-500mg taurine 0.5- 2 hrs before sex. In one embodiment, a volunteer took 50mL liquid formulation contains 100 mg of rotundine and 100 mg dehydrocorybulbine (DHCB) and 30mg of hyperforin and 30mg adhyperforin 0.5- 2 hrs before sex. In one
embodiment, a volunteer took a capsule containing 500 mg of curcumin and 60 mg of rotundine
410 and 60 mg dehydrocorybulbine (DHCB) and 60mg levostepholidine 2 hrs before sex. All these formulation can cause delayed ejaculation. Extract from danshen root, Panax notoginseng, Radix Angelicae Dahuricae, Rhizoma Cyperi Rotundi, Rhizoma and Ligustici Chuanxiong can also be added to the formulation (e.g. extract equals to 25g of bulk herb). The active compound from these extract (e.g. 500mg coumarin of angelicae dahuricae) can also be used instead of the crude
415 extract.
Furthermore, the above formulations can be added with dopamine receptor antagonist in effective therapeutical amount to increase their potency in increasing ejaculation latency. The combination of dopamine antagonist with SSRIs can provide better delaying ejaculation effect than using them alone. Examples of suitable dopamine antagonist include Chlorpromazine,
420 Pimozide, Metoclopramide, Sulpiride, Haloperidol. The dopamine antagonist can be dopamine
D3 receptor antagonist such as BP897, CAM89, NGB2904, NGB2849, PG619, CJB090, YQA14, PG01037, RGH188/canprazine, PG622, FAUC365, ST-198, SB-269652, SB-277011A, SB- 414796, R-PG648, PG01037, ABT-925, SR21502, GSK598809, GSK618334, BAK2-66, Buspirone, S33084 and S33138. They can be given to the person in need as an oral formulation
425 0.5 - 3 hrs before sex either alone or in combination with other ingredient such as SSRI,
hyperforin, curcumin or rotundine as described previously in the current disclosure. The amount used in the formulation to delay ejaculation generally is less than the amount (e.g. 20% -90) of that used in clinics for other indication using dopamine antagonist. For example in one embodiment, a person in need can take 50mg GSK598809 or GSK618334 1-2 hrs before sex to
430 delay ejaculation; in another embodiment, a person in need can take 30mg GSK598809 and 1000 mg 2 hrs before sex. In another example, a person in need can take 30mg GSK598809 and 100 mg L-tetrahydropalmatine lhr before sex. In another example, a person in need can take 30mg GSK598809 and 100 mg L-tetrahydropalmatine and 30mg caffeinelhr before sex. In another example, a person in need can take 30mg GSK598809 and 10 mg escitalopram l-2hrs before sex.
435 In another example, a person in need can take 30mg GSK598809 and 500 mg curcumin l-2hrs before sex. In another example, a person in need can take 30mg GSK598809 and 20 mg hyperforin l-2hrs before sex. In another example, a person in need can take 5mg Buspirone and 10 mg escitalopram l-2hrs before sex. In another embodiment, a person in need can take 3mg Cariprazinel-2 hrs before sex to delay ejaculation; in another embodiment, a person in need can
440 take 2 mg Cariprazine and 1000 mg 2 hrs before sex. In another example, a person in need can take 3mg Cariprazine and 100 mg L-tetrahydropalmatine lhr before sex. In another example, a person in need can take 3mg Cariprazine and 100 mg L-tetrahydropalmatine lhr before sex. In another example, a person in need can take 3mg Cariprazine and 10 mg escitalopram l-2hrs before sex. In another example, a person in need can take 30mg Cariprazine and 500 mg
445 curcumin l-2hrs before sex. In another example, a person in need can take 3mg Cariprazine and 20 mg hyperforin 1 -2hrs before sex.
Preferably the dosage form used for the current invention is an orally taken formulation such as capsule, liquid capsule, tablet, lozenge, emulsion, solution and etc, which contains
therapeutically effective amount of active ingredient and pharmaceutically acceptable excipients 450 such as starch, cellulose, gelatin and etc, which is well known to the skilled in the art.

Claims

CLAIMS What is claimed is:
1. A method of managing sexual dysfunction or improving sexual control in a mammal in need of treatment comprising administering on an as-needed basis to the mammal a composition comprising tetrahydropalmatine and serotonin reuptake inhibitor in a therapeutically effective amount.
2. The method of claim 1, wherein the mammal is a human male.
3. The method of claim 1, wherein the serotonin reuptake inhibitor is selected from a group consisting of St. John's Wort extract, hyperforin, paroxetine, sertraline, dapoxetine, escitalopram and citalopram.
4. A method of managing sexual dysfunction or improving sexual control in a mammal in need of treatment comprising administering on an as-needed basis to the mammal a composition comprising Corydalis Yanhusuo extract in a therapeutically effective amount.
5. The method of claim 4, wherein the composition further comprise St. John's Wort extract.
6. The method of claim 4, wherein the composition further comprise curcuminoid.
7. A formulation for delaying ejaculation comprising Corydalis extract or tetrahydropalmatine, curcuminoid and at least one agent selected from a group consisting of paroxetine, sertraline, dapoxetine, Escitalopram, Citalopram and St. John's Wort extract.
8. The formulation of claim 7 wherein the curcuminoid is selected from a group consisting of curcumin, desmethoxycurcumin, bis-desmethoxycurcumin, tetrahydrocurcuminoid, curcumin glucuronide, curcumin sulfate, hexahydrocurcumin or combinations thereof.
9. The formulation of claim 7, wherein the St. John's Wort extract is rich in hyperforin.
PCT/US2017/063208 2016-11-30 2017-11-26 Therapeutical methods, formulations and nutraceutical formulations WO2018102233A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427816P 2016-11-30 2016-11-30
US62/427,816 2016-11-30

Publications (1)

Publication Number Publication Date
WO2018102233A1 true WO2018102233A1 (en) 2018-06-07

Family

ID=62241905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/063208 WO2018102233A1 (en) 2016-11-30 2017-11-26 Therapeutical methods, formulations and nutraceutical formulations

Country Status (1)

Country Link
WO (1) WO2018102233A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2023581B1 (en) * 2019-07-29 2021-02-22 Atlas Pharmaceuticals Bv Serotonergic agent and 5-HT1A-receptor antagonist

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200524582A (en) * 1999-09-03 2005-08-01 Apbi Holdings Llc Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2008037045A2 (en) * 2006-09-28 2008-04-03 Medley S.A. Indústria Farmacêutica Composition containing a mixture of antidepressants for treating premature ejaculation.
WO2010057503A2 (en) * 2008-11-20 2010-05-27 El-Sayed Ameen Mahmoud Rezq Long acting conserved natural functional groups curcumin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200524582A (en) * 1999-09-03 2005-08-01 Apbi Holdings Llc Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2008037045A2 (en) * 2006-09-28 2008-04-03 Medley S.A. Indústria Farmacêutica Composition containing a mixture of antidepressants for treating premature ejaculation.
WO2010057503A2 (en) * 2008-11-20 2010-05-27 El-Sayed Ameen Mahmoud Rezq Long acting conserved natural functional groups curcumin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"?p??o???ec??? pi?ac??iotap? ZB Prostatic Navel Plaster: o???iota? ?pa?a, ??? ??pi???", UROLOGIC PLASTER ZB PROSTATIC NAVEL PLASTER: A DOCTOR OPINION, WHERE TO BUY?, 25 January 2016 (2016-01-25), Retrieved from the Internet <URL:http://bodytransform.ru/urologicheskij-plastyr-zb-prostatic-navel-plaster-otzyv-vracha-gde-kupit.html> [retrieved on 20180420] *
ST JOHN'S WORT, 29 August 2013 (2013-08-29), Retrieved from the Internet <URL:https://europensp.wordpress.com/2013/08/29/st-johns-wort> [retrieved on 20180420] *
XOX?A??A PIO?A?. ?E?E??IOTAE ? PA??IOTA., 29 August 2013 (2013-08-29), Retrieved from the Internet <URL:https://web.afchive.ofg/web/20160806034755/http://www.medherb.ru/cor_ca.htm> [retrieved on 20180420] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2023581B1 (en) * 2019-07-29 2021-02-22 Atlas Pharmaceuticals Bv Serotonergic agent and 5-HT1A-receptor antagonist

Similar Documents

Publication Publication Date Title
US7438934B2 (en) Formulations useful in the treatment of male and female impotence
JP5840703B2 (en) Water-soluble composition comprising curcumin having enhanced bioavailability and process for its preparation
US6787164B2 (en) Composition and method for treating the effects of diseases and maladies
US20200060992A1 (en) Therapeutical methods, formulations and nutraceutical formulations
US20020006445A1 (en) Composition and method for treating the effects of diseases and maladies
US20020128273A1 (en) Composition and method for treating the effects of diseases and maladies
JP4603351B2 (en) Formulations useful in the treatment of male and female impotence
US10286028B2 (en) Compositions containing extracts of Curcuma longa and Echinacea angustifolia which are useful to reduce peripheral inflammation and pain
US20010044411A1 (en) Composition and method for treating the effects of diseases and maladies
SK284937B6 (en) Use of prokinetically active antiemetic and tramadol for the manufacture of a medicament for the treatment of migraine
US11607406B2 (en) Therapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (en) Therapeutical methods, formulations and nutraceutical formulations
US20020034555A1 (en) Composition and method for treating the effects of diseases and maladies
CA3127291A1 (en) Method for enhancing .beta.-adrenergic response
Shinkar et al. Case study: Indian herbal bioenhancers
US12029771B2 (en) Neem for treatment of RLS
US20010043959A1 (en) Composition and method for treating the effects of diseases and maladies
JPH06183988A (en) Preventive for bladder cancer
CN104473957B (en) A kind of Chinese medicine monomer compositions for blood fat reducing and preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17876083

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17876083

Country of ref document: EP

Kind code of ref document: A1